Radioembolization in the setting of liver transplantation: great expectations or hard times?

Radioembolization in the setting of liver transplantation: great expectations or hard times?

Quirino Lai, Gianluca Mennini

Hepato-bilio-pancreatic and Liver Transplant Unit, Department of Surgery, Sapienza University of Rome, Rome, Italy

Correspondence to: Quirino Lai, MD, PhD. Department of General Surgery and Organ Transplantation, Hepato-bilio-pancreatic and Liver Transplant Unit, Sapienza University of Rome, Umberto I Policlinic of Rome, Viale del Policlinico 155, 00161 Rome, Italy. Email:

Provenance: This is an invited Editorial commissioned by Editor-in-Chief Yilei Mao (Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China).

Comment on: Levi Sandri GB, Ettorre GM, Colasanti M, et al. Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation. Hepatobiliary Surg Nutr 2017;6:44-8.

Submitted Dec 12, 2017. Accepted for publication Dec 22, 2017.

doi: 10.21037/hbsn.2017.12.10

Trans-arterial radio-embolization (TARE) with yttrium-90 represents one of the most efficacious approaches for the treatment of selected patients with advanced hepatocellular cancer (HCC) (1). Recent studies have confirmed the superiority of TARE when compared with other intra-arterial treatments (2,3). A randomized phase II study comparing TARE and trans-arterial chemo-embolization (TACE) in HCC patients meeting Barcelona Clinic Liver Cancer stages A-B showed a longer median time-to-progression (>26 vs. 6.8 months; P value =0.001), and a better tumor control in post-TARE cases (2). Another study similarly compared TARE and TACE patients homogeneously selected using a propensity score matching: also in this case, TARE presented higher overall complete response rates (84% vs. 58%; P value <0.001), and longer median progression-free survivals (564 vs. 271 days; P value =0.002) (3).

In the specific setting of advanced HCC, TARE presents the undoubtful benefit of being the sole strategy, apart sorafenib, able to treat tumor-related portal vein thrombosis (PVT). A propensity score match analysis comparing TARE and sorafenib showed similar efficacy in terms of tumor control and progression (4). A systematic review based on 722 patients further confirmed that TARE is a safe and effective treatment for HCC patients with PVT (5). However, prospective randomized studies are still lacking in this specific setting (6).

It is clear that the opportunity to use TARE for efficaciously down-stage advanced and not-transplantable cases, even initially presenting macrovascular invasion, represents an attractive opportunity for liver transplantation (LT) physicians (7-9). A study comparing 172 HCC cases initially bridged/down-staged with different approaches (TARE =93; TACE =79) and then undergoing LT showed a trend towards better recurrence-free survivals in down-staged patients treated with TARE (7). Another study specifically investigating the ability of TARE vs. TACE to down-stage HCC cases from a Milan Criteria (MC)-OUT to a MC-IN status, showed that TARE was superior in terms of partial response rates (61% vs. 37%) and down-staging achievement (58% vs. 31%) (8).

In a recent study by Levi Sandri et al., four cases even presenting initial tumor-related PVT were first down-staged and then efficaciously transplanted (9). Interestingly enough, these four cases corresponded to approximately 20% of all the cases down-staged using TARE, further suggesting that the systematic use of TARE should present a non-marginal role in improving the number of potentially transplantable patients. Another interesting aspect to underline was the very long waiting time reported from TARE to LT, with a mean time of approximately 16 months. As a matter of fact, in absence of available intention-to-treat analyses, it sounds acceptable that the proof of time should be retained necessary with the intent to select post-TARE good-responders.

However, some concerns may also be addressed with regard to the liberal use of TARE. Obviously, the high costs of the procedure should be at least balanced by a congruous number of patients efficaciously down-staged. A risk of radiological overestimation of post-TARE response exists.

A study comparing radiological and pathological response after TARE showed that different radiological criteria like the modified response evaluation criteria in solid tumors were not able to reliably predict complete pathological necrosis (10). Another study confirmed such an evidence, however reporting that post-TARE imaging findings of response were somehow predictive of the degree of pathologic necrosis (11).

This evidence further corroborates the attitude of Levi Sandri et al. to await for at least 6 months before LT, with the intent to confirm the effective validity of the radiological findings. In light of this, we should like to underline the role of biological markers like the alpha-fetoprotein (AFP) slope, as an important tool for selecting patients with HCC progression. In the series reported by Levi Sandri et al., all the cases showed an AFP slope reduction, thus confirming the efficacy of the treatment.

Another important aspect to consider is the risk of post-TARE toxicity. Such an aspect is important mainly for patients waiting for LT, due to the possible risk of drop-out after liver decompensation. As a matter of fact, TARE should be considered only in case of patients at low-risk of being jeopardized by its use.

A systematic review based on 31 observational studies reported different complications (i.e., gastric ulcers, hepatic encephalopathy, cholecystitis, hepatic failure, pleural effusion, ascites, nausea) (12).

It is however clear that TARE represents an extraordinary opportunity for HCC patients, mainly in case of PVT. Recent studies comparing TARE and sorafenib (13) or hypothesizing their combinative role (14) showed very interesting preliminary results.

A recent study by Salem et al. further confirmed the great expectations for TARE: after a 15-year long experience and a series of 1,000 patients treated with TARE, the centre of Chicago has recently decided to adopt TARE as the first-line trans-arterial loco-regional treatment for all the patients with HCC (15).

In conclusion, TARE represents an excellent therapy for advanced HCC patients, mainly in presence of PVT. Only a very limited number of article exists investigating the opportunity to transplant patients initially presenting macrovascular invasion and efficaciously down-staged with TARE. It looks clear that intention-to-treat analyses are required, mainly with the intent to understand how many patients will be able to be down-staged to criteria of transplantability. A mandatory waiting-time of at least 6 months looks to be another important strategy in this specific setting. Our opinion is that in the next future hard times may be unfortunately postulated for non-responders, mainly in terms of tumor progression, toxicity and liver decompensation. However, also great expectations may exist for patients efficaciously treated.




Conflicts of Interest: The authors have no conflicts of interest to declare.


  1. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497-507.e2. [Crossref] [PubMed]
  2. Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016;151:1155-63.e2. [Crossref] [PubMed]
  3. Padia SA, Johnson GE, Horton KJ, et al. Segmental yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: Results of a single-center, retrospective, propensity score-matched study. J Vasc Interv Radiol 2017;28:777-85.e1. [Crossref] [PubMed]
  4. Cho YY, Lee M, Kim HC, et al. Radioembolization is a safe and effective treatment for hepatocellular carcinoma with portal vein thrombosis: a propensity score analysis. PLoS One 2016;11:e0154986. [Crossref] [PubMed]
  5. Jia Z, Jiang G, Tian F, et al. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol 2016;22:353-59. [Crossref] [PubMed]
  6. Finn RS, Zhu AX, Farah W, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis. Hepatology 2018;67:422-35. [Crossref] [PubMed]
  7. Gabr A, Abouchaleh N, Ali R, et al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. Eur J Radiol 2017;93:100-6. [Crossref] [PubMed]
  8. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9:1920-28. [Crossref] [PubMed]
  9. Levi Sandri GB, Ettorre GM, Colasanti M, et al. Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation. Hepatobiliary Surg Nutr 2017;6:44-8. [Crossref] [PubMed]
  10. Vouche M, Kulik L, Atassi R, et al. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology 2013;58:1655-66. [Crossref] [PubMed]
  11. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009;49:1185-93. [Crossref] [PubMed]
  12. Kallini JR, Gabr A, Thorlund K, et al. Comparison of the adverse event profile of TheraSphere® with SIR-Spheres® for the treatment of unresectable hepatocellular carcinoma: A systematic review. Cardiovasc Intervent Radiol 2017;40:1033-43. [Crossref] [PubMed]
  13. Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol 2014;61:309-17. [Crossref] [PubMed]
  14. Vilgrain V, Pereira H, Assenat E, et al. SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017;18:1624-36. [Crossref] [PubMed]
  15. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology 2017. [Epub ahead of print]. [PubMed]
Cite this article as: Lai Q, Mennini G. Radioembolization in the setting of liver transplantation: great expectations or hard times? Hepatobiliary Surg Nutr 2018;7(1):58-60. doi: 10.21037/hbsn.2017.12.10